Radiation dosimetry, pharmacokinetics, and safety of ultratrace™ iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 4, 2009, Pages 469-475

  Coleman, R Edward ^a   Stubbs, James B ^b   Barrett, John A ^c   De La Guardia, Miguel ^c   Lafrance, Norman ^c   Babich, John W ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Radiation Dosimetry Systems Inc   (United States)

^c A Subsidiary of Lantheus Holdings   (United States)

Author keywords

Carcinoid; Metaiodobenzylguanidine; MIBG; Molecular Insight Pharmaceuticals; Neuroendocrine tumor; Paraganglioma; Pheochromocytoma; Radiotherapy; Ultratrace 131I MIBG

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 131; 3 IODOHIPPURIC ACID; 5 HYDROXYINDOLEACETIC ACID; CHROMOGRANIN A; DRUG METABOLITE; IODIDE; IODINE 131; IODOHIPPURIC ACID; METADRENALIN; RADIOACTIVE IODINE; ULTRATRACE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CARCINOID; CLINICAL ARTICLE; CLINICAL TRIAL; DOSIMETRY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HUMAN; ISOTOPE LABELING; MALE; METASTASIS; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; WHOLE BODY IMAGING;

3-IODOBENZYLGUANIDINE; ADRENAL GLAND NEOPLASMS; ADULT; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; PARAGANGLIOMA; PHEOCHROMOCYTOMA; RADIATION DOSAGE; RADIOMETRY; RADIOPHARMACEUTICALS;

EID: 69249133840     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0584     Document Type: Article

References (19)

1. Brendel AJ, Jeandot R, Guyot M, et al. Radionuclide therapy of pheochromocytomas and neuroblastomas using iodine- 131 metaiodobenzylguanidine (MIBG). Clin Nucl Med 1989; 14:19.
2. 131I-metaiodobenzylguanidine (131-I-MIBG). Ann N Y Acad Sci 2006;1073:465.
3. Forssell-Aronsson E, Bernhardt P, Wangberg B, et al. Aspects on radionuclide therapy in malignant pheochromocytomas. Ann N Y Acad Sci 2006;1073:498.
4. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2008;35:725.
5. Kvols LK. Neoplasms of the diffuse endocrine system. In: Kufe DW, et al. (eds.), Cancer Medicine, 6th ed, Hamilton, Ontario, Canada: BC Decker Inc., 2003.
6. 131I- metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 2003;98:239.
7. Safford SD, Coleman RE, Gockerman JP, et al. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer 2004;101:1987.
8. Safford SD, Coleman RE, Gockerman JP, et al. Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 2003;134:956.
9. 123IMIBG: An initial clinical study in patients with phaeochromocytoma. Nucl Med Commun 2000;21:437.
10. 131I] meta- iodobenzylguanidine: Implications for the targeted radiotherapy of neuroblastoma. Eur J Cancer 1995;31:576.
11. Iobenguane Sulfate I-131 Injection Diagnostic-For Intravenous Use. [package insert]. Bedford, MA: CIS-US, Inc., July, 1999.
12. 131I]metaiodobenzyl guanidine for the treatment of tumors transfected with the noradrenaline transporter gene. Lett Drug Des Dis 2004;1:50.
13. Vaidyanathan G, Zalutsky MR. No-carrier-added synthesis of meta-[131-I]iodobenzylguanidine Appl Radiat Isot 1993;44:621.
14. Nakajo M, Shapiro S, Copp J, et al. The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (I-131 MIBG) in man: Evaluation by scintigraphy. J Nucl Med 1983;24:672.
15. Brill AB, Stabin M, Bouville A, et al. Normal organ radiation dosimetry and associated uncertainties in nuclear medicine, with emphasis on iodine-131. Radiat Res 2006;166:128.
16. McEwan AJ, Shapiro B, Sisson JC, et al. Radioiodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors. Semin Nucl Med 1985;15:132.
17. Stabin MG, Sparks RB, Crowe E. OLINDA=EXM: The second- generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023.
18. Stabin MG, Flux GD. Internal dosimetry as a tool for radiation protection of the patient in nuclear medicine. Biomed Imaging Interv J 2007;3:3.
19. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys May 15;21(1):109 (1991).